Edition:
United States

Interpace Diagnostics Group Inc (IDXG.OQ)

IDXG.OQ on NASDAQ Stock Exchange Capital Market

1.02USD
14 Dec 2018
Change (% chg)

$0.02 (+2.00%)
Prev Close
$1.00
Open
$1.00
Day's High
$1.02
Day's Low
$0.97
Volume
16,692
Avg. Vol
75,163
52-wk High
$1.78
52-wk Low
$0.77

Latest Key Developments (Source: Significant Developments)

Interpace Diagnostics Group Inc Files For Mixed Shelf Of Upto $50 Million - SEC Filing
Friday, 5 Oct 2018 05:51pm EDT 

Oct 5 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS GROUP INC FILES FOR MIXED SHELF OF UPTO $50 MILLION - SEC FILING.  Full Article

Interpace Diagnostics Announces Reimbursement Expansion Of Thygenext
Monday, 24 Sep 2018 06:55am EDT 

Sept 24 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS ANNOUNCES REIMBURSEMENT EXPANSION OF THYGENEXT™.INTERPACE DIAGNOSTICS GROUP - GETS APPROVAL TO LAUNCH THYGENEXT, IN STATES OF PENNSYLVANIA AND NEW YORK.INTERPACE DIAGNOSTICS GROUP - PENNSYLVANIA APPROVAL IS FINAL, NEW YORK STATE APPROVAL CONDITIONED UPON RECEIPT OF ADDITIONAL INFORMATION REQUESTED.  Full Article

Interpace Diagnostics Group Q1 Revenue Rises 39 Percent
Tuesday, 15 May 2018 08:00am EDT 

May 15 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS, BUSINESS PROGRESS AND RECENT ACCOMPLISHMENTS.Q1 REVENUE ROSE 39 PERCENT TO $4.8 MILLION.QTRLY LOSS PER SHARE $0.11.  Full Article

Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offering​
Thursday, 16 Nov 2017 08:00am EST 

Nov 16 (Reuters) - Interpace Diagnostics Group Inc -:Interpace Diagnostics Group Inc- ‍New York State Department Of Health has reviewed and approved for marketing co's TERT service offering​.  Full Article

Interpace Diagnostics says Q3 sales up 27 pct
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Interpace Diagnostics Group Inc ::Interpace diagnostics group reports third quarter 2017 financial results, business progress and recent accomplishments.Q3 sales rose 27 percent to $4.2 million.Interpace diagnostics group inc qtrly ‍net loss per diluted share of common stock $0.15​.  Full Article

Interpace Diagnostics announces national contract with Aetna
Wednesday, 28 Jun 2017 08:15am EDT 

June 28 (Reuters) - Interpace Diagnostics Group Inc :Interpace Diagnostics announces national contract with Aetna.Interpace Diagnostics Group -Signed new national contract with Aetna for its THYGENX and Thyramir molecular tests for indeterminate thyroid nodules​.  Full Article

Interpace Diagnostics files for offering of up to $13.8 mln
Monday, 22 May 2017 06:54am EDT 

May 22 (Reuters) - Interpace Diagnostics Group Inc ::Files for offering of up to $13.8 million .Interpace Diagnostics Group - offering for shares of co's common stock and pre-funded warrants to purchase shares of its common stock.  Full Article